drugset / Trial / NCT01284309

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

NCT01284309

Phase 1 Completed 321 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to assess the affect of mirabegron on intraocular pressure (IOP) in healthy subjects.

Timeline

Start
2010-11
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 100 mg Oral

Indications

No indication recorded.